LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human ...

Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products. This includes a program of targeted price reductions for several Harrow products and a ...

Gregg T. Kokame, MD, MMM, FASRS, is set to share data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured ...

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development. Arctic Vision has signed a new commercial collaboration agreement with ...

A program from National Health Service (NHS) England will bring optical coherence tomography (OCT) scans “closer to home” for thousands of patients. As part of an effort to improve outcomes for ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...

This year’s Barcelona meeting brought together award-winning research findings and leaders in the retina field. The European Society of Retina Specialists (Euretina) held its 24th annual congress in ...

Like many, I was privileged to attend the annual American Academy of Ophthalmology (AAO) meeting in Chicago, Illinois, in October. As an educator, a highlight is always hearing updates from former ...

AlloVir, Inc. has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock transaction. Under the terms of the agreement, AlloVir will acquire 100% of the ...